Search
Retatrutide Treatment Options in Illinois
A collection of 7 research studies where Retatrutide is the interventional treatment. These studies are located in the Illinois, United States. Retatrutide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
1 - 7 of 7
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Alliance for Multispecialty Research, LLC, Oak Brook, Illinois +1 locations
Conditions: Obesity
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwestern University, Chicago, Illinois +2 locations
Conditions: Obesity, Cardiovascular Diseases
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Active Not Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additiona... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Obesity, Overweight, Obstructive Sleep Apnea, Osteoarthritis, Knee
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Active Not Recruiting
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity, Overweight, Osteo Arthritis Knee
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/17/2025
Locations: Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois +6 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes